ClinicalTrials.gg
CompletedNCT01420653Updated Dec 6, 2018Results posted

Maxigesic 325 Acute Dental Pain Study

A Phase 3 interventional study of Maxigesic 325 and Acetaminophen in Dental Pain, sponsored by AFT Pharmaceuticals, Ltd.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-12-06.

Sponsored by AFT Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo.

Read the detailed description

The combination of 500mg acetaminophen and 150mg ibuprofen has been shown to improve analgesia compared with the individual components, when given as 2 tablets (i.e. total of 1,000/300 mg) 4 times a day.

Recent concerns over the safety of acetaminophen have led to some regulatory agencies restricting the maximum dose of acetaminophen per tablet to 325 mg, while maintaining the maximum daily dose of 4000mg per day.

A dosing regimen of three tablets of Maxigesic 325 four times a day gives a total daily dose of 3900mg acetaminophen and 1170mg ibuprofen.

The primary objective of the study is to compare time-adjusted SPID of the VAS pain intensity scores up to 48 hours after the first dose of study medication among the four study groups.

Secondary objectives are:

To compare the time to onset of pain relief after the first dose of study drug defined as (i) perceptible and (ii) meaningful pain relief among the four study groups using the two stopwatch method.

To compare the maximum VAS pain scores up to 48 hours after the first dose of study medication among the four study groups.

To compare the response rates (response rate to be defined as the percentage of participants who reduce their pain intensity scores by at least 50% compared with the baseline VAS measure) among the four study groups.

To compare the time to peak reduction in VAS pain intensity scores following the first dose of study medication among the four study groups.

To compare the time to requirement for rescue medication among the four study groups.

To compare the percentage of participants who use rescue medication among the four study groups.

To compare the amount of rescue medication used (defined as number of tablets) among the four study groups.

To compare the categorical global pain rating among the four study groups.

Safety:

To compare adverse event rates for the 48-hour study period and up to Day 30 among the four treatment groups.

To compare the incidence of known specific NSAID and paracetamol side effects (e.g. GI ulceration or bleeding, indigestion/stomach pain, post-operative bleeding, bronchospasm, skin rashes, water retention, renal failure, thromboembolic events and evidence of clinical hepatitis) during the 48-hour study period and up to Day 30 among the four study groups.

Planned hospital admissions and/or surgical operations for an illness or disease which existed before the study drug was given or the participant was randomized in the study will not be considered adverse events.

02

Conditions studied

  • Dental Pain

Browse trials for

03

In context

Toothache

143 studies on the registry are indexed under Toothache; 28 are open to participants now.

This study's enrollment of 408 is above the median of 84 across 123 interventional studies indexed under Toothache.

Browse Toothache studies →

Lead sponsor

AFT Pharmaceuticals, Ltd. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provides written before initiation of any study-related procedures.
  • Males and females aged at least 10 years and not more than 60 years old on the day of consent.
  • Undergoing dental surgery for the extraction of at least 2 impacted third molar teeth.
  • A resting VAS pain intensity score at baseline (within 6 hours after the completion of surgery) of greater than or equal to 40 mm on a 100 mm VAS scale with 0 = no pain and 100 = worst pain imaginable.

Exclusion criteria

Exclusion Criteria:

  • Has taken any NSAID or acetaminophen within 12 hours prior to the stat of surgery other than asprin less than or equal to 150 mg/day
  • Subjects who have received any anaesthetics within 24 hours prior to surgery
  • to opioids
  • Known to be pregnant or possibly pregnant
  • Women of who are unwilling to take adequate precautions, i.e., hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence. A women of childbearing potential is defined as any female who is less than 2 years or has not undergone a partial or total hysterectomy or surgical sterilization, e.g. bilateral tubal ligation, bilateral oophorectomy.
  • Women of childbearing potential who are unwilling to undergo an urine pregnancy test.
  • Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the investigator, makes the subject unsuitable from an efficacy or safety perspective.
  • In the opinion of the investigator, unable to understand the visual analogue pain score or comply with the protocol requirements.
  • Currently, or in the last 30 days, has been in a clinical trial involving another study drug.
  • Currently treated with an ACE inhibitor, warfarin, (other than nasal steroids or topical steroids with the approval of the investigator) cyclosporin, tacrolimus or methotrexate, or any other medication felt by the investigator to interfere with safety or efficacy evaluations.
  • Participant weight \< 50 kg or > 120 kg.
  • Has a history of drug or alcohol abuse.
  • Suffering from any other disease or condition which, in the opinion of the investigator, means that it would not be in the participants best interests to participant in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    Maxigesic 325

    Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally

    Drug: Maxigesic 325

  • Active comparator
    Acetaminophen

    Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally

    Drug: Acetaminophen

  • Active comparator
    Ibuprofen

    Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally

    Drug: Ibuprofen

  • Placebo comparator
    Placebo

    Placebo tablets, every 6 hours, orally

    Drug: Placebo

Interventions

  • DrugMaxigesic 325

    Drug pages: Acetaminophen · Ibuprofen

    Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours

    Also known as: Maxigesic

  • Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours

    Also known as: paracetamol

  • Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.

  • DrugPlacebo

    placebo, three tablets four times a day, with food for 48 hours

06

What researchers measure

Primary outcomes

  1. SPID (Summed Pain Intensity Differences)

    The time-adjusted Summed Pain Intensity Differences (SPIDs) of the VAS pain intensity scores up to 48 hours after the first dose of study medication. This was calculated from the visual analogue scale (VAS) pain intensity scores recorded during the 48 hours double blind treatment period, with the last measure taken just prior to the final dose of blinded study medication. The visual analogue scale is 100mm long with 0= no pain and 100=worst pain imaginable. The Visual Analogue Scale It is expected that treatments which can provide superior analgesic effect will demonstrate a greater Summed Pain Intensity Difference.

    Time frame: 48 hours afte the first dose

07

Results

Posted Dec 6, 2018

Participant flow

455 Subjects have been consented and screened, out of which 47 subjects were screening failures and did not receive the first dose of study medication. Among 408 subjects, 273 subjects enrolled from New Zealand sites and 135 subjects enrolled from USA site from May 2013 to Jan 2015.

Participant flow — Overall Study
MilestoneMaxigesic 325AcetaminophenIbuprofenPlacebo
Started11011111275
Completed10710810868
Not completed3347

Outcome measures

PrimarySPID (Summed Pain Intensity Differences)

The time-adjusted Summed Pain Intensity Differences (SPIDs) of the VAS pain intensity scores up to 48 hours after the first dose of study medication. This was calculated from the visual analogue scale (VAS) pain intensity scores recorded during the 48 hours double blind treatment period, with the last measure taken just prior to the final dose of blinded study medication. The visual analogue scale is 100mm long with 0= no pain and 100=worst pain imaginable. The Visual Analogue Scale It is expected that treatments which can provide superior analgesic effect will demonstrate a greater Summed Pain Intensity Difference.

Time frame:
48 hours afte the first dose
Reported as:
Mean · score on a scale
SPID (Summed Pain Intensity Differences)
score on a scaleMaxigesic 325AcetaminophenIbuprofenPlacebo
SPID (Summed Pain Intensity Differences)31.56 ± 1.9417.71 ± 1.8923.18 ± 1.8914.86 ± 2.26

Adverse events

Collected over Treatment-emergent Adverse Events were collected from the randomization to the follow up telephone contact made at 30 days after the surgery (Surgery Day is Day 1). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maxigesic 3251/110 (0.9%)1/110 (0.9%)41/110 (37.3%)
Acetaminophen0/111 (0%)0/111 (0%)54/111 (48.6%)
Ibuprofen0/112 (0%)0/112 (0%)40/112 (35.7%)
Placebo0/75 (0%)0/75 (0%)38/75 (50.7%)
Most frequent serious events
Most frequent serious events
EventMaxigesic 325AcetaminophenIbuprofenPlacebo
Death due gun shotInjury, poisoning and procedural complications1/1100/1110/1120/75
Most frequent other events
Most frequent other events
EventMaxigesic 325AcetaminophenIbuprofenPlacebo
NauseaGastrointestinal disorders15/11019/11115/11217/75
VomitingGastrointestinal disorders9/11014/1115/1127/75
HeadacheNervous system disorders8/1109/1119/1127/75
Facial swellingSkin and subcutaneous tissue disorders6/11010/1118/1125/75
DizinessNervous system disorders4/1105/1113/1125/75

Baseline characteristics

Age, Continuous
Age, Continuous(years)Maxigesic 325AcetaminophenIbuprofenPlaceboTotal
Mean25.4 ± 7.025.0 ± 6.924.3 ± 5.924.3 ± 6.324.8 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Maxigesic 325AcetaminophenIbuprofenPlaceboTotal
Female69768248275
Male41353027133
Region of Enrollment
Region of Enrollment(participants)Maxigesic 325AcetaminophenIbuprofenPlaceboTotal
New Zealand73757550273
United States37363725135
08

Study locations

4 sites
  • Premier Research
    Austin, Texas 78705, United States
  • Clinical Trial New Zealand
    Hamilton, Waikato, New Zealand
  • Clinical Solutions Ltd.
    Auckland, 0622, New Zealand
  • Southern Clinical Trials
    Christchurch, New Zealand
09

References and documents

Publications

  • Daniels SE, Atkinson HC, Stanescu I, Frampton C. Analgesic Efficacy of an Acetaminophen/Ibuprofen Fixed-dose Combination in Moderate to Severe Postoperative Dental Pain: A Randomized, Double-blind, Parallel-group, Placebo-controlled Trial. Clin Ther. 2018 Oct;40(10):1765-1776.e5. doi: 10.1016/j.clinthera.2018.08.019. Epub 2018 Sep 21. PubMed 30245281 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Dec 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2018, 4 years after primary completion. A results delay was requested in Feb 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2011
First posted
Aug 22, 2011
Start
Apr 2013
Primary completionActual
Dec 2014
CompletionActual
Jan 2015
Results delay requested
Feb 15, 2016
Results first posted
Dec 6, 2018
Last update
Dec 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01420653
Lead sponsor
AFT Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Aug 22, 2011
Start date
Apr 2013
Primary completion
Dec 2014
Completion
Jan 2015
Results posted
Dec 6, 2018
Last update
Dec 6, 2018

Study contacts

John Currie, Doctor
principal investigator · Clinical Trial New Zealand

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Ibuprofen

Start the discussion